

**hVIVO plc**  
("hVIVO", the "Company" or the "Group")

**Directorate Change**  
*Appointment of Independent Non-Executive Director*

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that further to its announcement on 12 May 2025, the Company has appointed Tracey James as Independent Non-Executive Director from 1 June 2025. Tracey will be Chair of the Audit Committee, and a member of the Remuneration and Nominations Committees.

Tracey is a Chartered Accountant with 26 years' experience working at Grant Thornton UK LLP (Grant Thornton), including 14 years as an Audit Partner. Tracey was a member of Grant Thornton's Oversight Board and also served on the Audit & Risk and Pensions Committees. She has held roles as Director of Finance at Karl Storz Endoscopy Canada, as Senior Independent Director, and Chair of Audit at CT Automotive Group plc and as Vice Chair and Chair of Audit & Risk and a member of the Remuneration Committee at Activate Learning Group. Tracey was also Non-Executive Director and member of the Audit Committee at Places for People Group.

Currently Tracey is a Non-Executive Director at ECO Animal Health Group plc and Gattaca plc. She is also Chair of the Audit & Risk Committee and a member of the Remuneration Committee for both companies.

**Yamin 'Mo' Khan, Chief Executive Officer of hVIVO plc, said:** "We are delighted to welcome Tracey to the Board of hVIVO. Tracey brings with her a wealth of experience, especially with AIM listed companies, that will further strengthen the Board. I look forward to working with Tracey and leaning on her expertise as we continue to integrate our diverse portfolio of revenue streams and deliver further progress for our clients and shareholders."



**Tracey James**  
**Independent Non-Executive Director**

**Additional Information on the Board Appointment**

The following additional information is provided with regards to the appointment of Tracey Dawn James (née Clements), aged 62, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

**Current directorships/partnerships:**

ECO Animal Health Group plc  
Gattaca plc

**Former directorships/partnerships (within the last five years):**

Activate Learning Group (Charity)  
Allenbuild Limited  
CT Automotive Group plc  
Millwood Designer Homes Limited  
Modularwise Limited  
Places for People Developments Limited  
Places for People Group Limited  
Places for People Ventures Limited  
Places for People Ventures Operations Limited  
Zeroc Group (2008) Limited

Tracey does not hold any shares or options in the Company.

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

**For further information please contact:**

**hVIVO plc** +44 (0)20 7756 1300  
Yamin 'Mo' Khan, Chief Executive Officer  
Stephen Pinkerton, Chief Financial Officer

**Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)** +44 (0)20 7220 0500  
Geoff Nash, Callum Davidson  
Trisyia Jamaludin, Harriet Ward  
Nigel Birks - Life Science Specialist Sales  
Louise Talbot - Sales

**Peel Hunt LLP (Joint Broker)** +44 (0)20 7418 8900  
James Steel, Dr Christopher Golden

**Davy (Joint Broker)** +353 (0) 1 679 6363  
Anthony Farrell, Niall Gilchrist

**Walbrook PR (Financial PR & IR)** +44 (0)20 7933 8780 or [hvivo@walbrookpr.com](mailto:hvivo@walbrookpr.com)



**Notes to Editors**

**hVIVO plc** (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London—the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the **hLAB** brand.

Through its German subsidiary, **CRS**, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, **Venn Life Sciences** offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via **FluCamp**. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAPPUUCAUPAGRR